Alps Advisors Inc. increased its position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 11.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 31,934 shares of the company’s stock after buying an additional 3,216 shares during the period. Alps Advisors Inc. owned about 0.09% of Aerie Pharmaceuticals worth $1,678,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Aerie Pharmaceuticals by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock worth $10,115,000 after buying an additional 49,473 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock worth $3,102,000 after buying an additional 3,739 shares in the last quarter. Turner Investments LLC bought a new stake in shares of Aerie Pharmaceuticals during the first quarter worth $227,000. Finally, Vanguard Group Inc. boosted its stake in shares of Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock worth $63,151,000 after buying an additional 92,463 shares in the last quarter. Institutional investors and hedge funds own 87.74% of the company’s stock.
Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 54.80 on Friday. The company’s market capitalization is $1.99 billion. The firm has a 50-day moving average of $54.37 and a 200 day moving average of $48.30. Aerie Pharmaceuticals, Inc. has a 12 month low of $18.52 and a 12 month high of $59.50.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, equities research analysts expect that Aerie Pharmaceuticals, Inc. will post ($2.56) earnings per share for the current fiscal year.
WARNING: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/18/aerie-pharmaceuticals-inc-aeri-position-raised-by-alps-advisors-inc.html.
A number of equities research analysts recently weighed in on AERI shares. HC Wainwright restated a “buy” rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, May 3rd. Needham & Company LLC lifted their price objective on shares of Aerie Pharmaceuticals from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Canaccord Genuity set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 22nd. Stifel Nicolaus restated a “buy” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $66.08.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $55.95, for a total value of $1,119,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 9.36% of the stock is owned by company insiders.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
